Hot Products

Basic Information

Post buying leads

Suppliers

Cas Database

Name	Amsacrine	EINECS	257-094-3
CAS No.	51264-14-3	Density	1.398 g/cm³
PSA	88.70000	LogP	5.73850
Solubility	N/A	Melting Point	230-240oC
Formula	C21H19 N3 O3 S	Boiling Point	563 °C at 760 mmHg
Molecular Weight	393.466	Flash Point	294.3 °C
Transport Information	N/A	Appearance	white solid
Safety	Poison by ingestion, intravenous, subcutaneous, and intraperitoneal routes. Human systemic effects by intravenous route: nausea or vomiting, thrombosis distant from injection site, and bone marrow changes. An experimental teratogen. Other experimental reproductive effects. Mutation data reported. When heated to decomposition it emits very toxic fumes of NO_x and SO_x.	Risk Codes	N/A
Molecular Structure		Hazard Symbols	N/A
Synonyms	4'-(9-Acridinylamino)methanesulfon-m-anisidide;AMSA; Acridinylanisidide; Amekrin; Amsacrine; Amsidil; Amsidine; Amsidyl; CI880; Lamasine; N-[4-(9-Acridinylamino)-3-methoxyphenyl]methanesulfonamide; NSC156303; NSC 249992; SN 11841; SN 21429; m-AMSA; m-Amsacrine	Article Data	8

Amsacrine Chemical Properties

IUPAC Name: N-[4-(acridin-9-ylamino)-3-methoxyphenyl]methanesulfonamide
Synonyms: 4'-(Acridinylamino)methanesulfon-m-anisidide ; AMSA, M- ; Methanesulfonamide, N-(4-(9-acridinylamino)-3-methoxyphenyl)- ; Methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]- ; N-[4-(9-Acridinylamino)-3-methoxuphenyl]methanesulfonamide ; N-[4-(9-Acridinylamino)-3-methoxyphenyl]methanesulfonamide ; N-[4-(acridin-9-ylamino)-3-(methyloxy)phenyl]methanesulfonamide ; N-[4-(acridin-9-ylamino)-3-methoxyphenyl]methanesulfonamide
Product Categories: Pharmaceutical material and intermeidates
Molecular Structure of 4'-(9-Acridinylamino)methanesulphon-m-anisidide (CAS NO.51264-14-3) :
Molecular Formula of 4'-(9-Acridinylamino)methanesulphon-m-anisidide (CAS NO.51264-14-3) : C₂₁H₁₉N₃O₃S
Molecular Weight of 4'-(9-Acridinylamino)methanesulphon-m-anisidide (CAS NO.51264-14-3) : 393.46
CAS NO: 51264-14-3
EINECS: 257-094-3
Mol File: 51264-14-3.mol
Index of Refraction: 1.722
Surface Tension: 65.6 dyne/cm
Density: 1.398 g/cm³
Flash Point: 294.3 °C
Enthalpy of Vaporization: 84.62 kJ/mol
Boiling Point: 563 °C at 760 mmHg
Vapour Pressure: 1.06E-12 mmHg at 25°C

Amsacrine Uses

4'-(9-Acridinylamino)methanesulphon-m-anisidide (CAS NO.51264-14-3) is used as Acridine anti-cancer drugs, mainly for a cellular inhibitor. The role of it's theory is similar to anthracycline. It is mainly used for acute lymphoblastic leukemia and bone marrow cells in treatment.

Amsacrine Production

Reaction of O-methoxy-p-nitroaniline with chloride ,protect amino-amidation , reduce the nitro to amino, which is amino-acylation by sulfonyl chloride to form sulfonyl amino, and then selectively hydrolysis, take off the fist amino-protecting groups, at last reaction with 9 - chloro-acridine, 4'-(9-Acridinylamino)methanesulphon-m-anisidide (CAS NO.51264-14-3) is obtained .

Amsacrine Toxicity Data With Reference

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
dog	LD50	intravenous	6250ug/kg (6.25mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: DYSPNEA	Cancer Treatment Reports. Vol. 64, Pg. 855, 1980.
dog	LD50	oral	50mg/kg (50mg/kg)	BEHAVIORAL: FOOD INTAKE (ANIMAL) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" GASTROINTESTINAL: NAUSEA OR VOMITING	Cancer Treatment Reports. Vol. 66, Pg. 1939, 1982.
human	TDLo	intravenous	12mg/kg (12mg/kg)	VASCULAR: THROMBOSIS DISTANT FROM INJECTION SITE GASTROINTESTINAL: NAUSEA OR VOMITING BLOOD: OTHER CHANGES	Cancer Research. Vol. 38, Pg. 3712, 1978.
man	LDLo	intravenous	5405ug/kg/3H- (5.405mg/kg)	BLOOD: CHANGES IN BONE MARROW NOT INCLUDED ABOVE	Archives of Internal Medicine. Vol. 143, Pg. 165, 1983.
monkey	LDLo	intravenous	10400ug/kg (10.4mg/kg)	BLOOD: CHANGES IN BONE MARROW NOT INCLUDED ABOVE	Pharmacy International. Vol. 7, Pg. 3, 1986.
mouse	LD50	intraperitoneal	15470ug/kg (15.47mg/kg)		National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986,
mouse	LD50	intravenous	33700ug/kg (33.7mg/kg)	BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: DYSPNEA	Cancer Treatment Reports. Vol. 64, Pg. 855, 1980.
mouse	LD50	oral	53420ug/kg (53.42mg/kg)		National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986,
mouse	LD50	subcutaneous	110mg/kg (110mg/kg)		National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986,

Amsacrine Consensus Reports

EPA Genetic Toxicology Program.

Amsacrine Safety Profile

Poison by ingestion, intravenous, subcutaneous, and intraperitoneal routes. Human systemic effects by intravenous route: nausea or vomiting, thrombosis distant from injection site, and bone marrow changes. An experimental teratogen. Other experimental reproductive effects. Mutation data reported. When heated to decomposition it emits very toxic fumes of NO_x and SO_x.
RIDADR 3249
HazardClass 6.1(b)
PackingGroup III

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 51264-14-3